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Abstract
Background: Medical studies are more likely to report favorable findings when a conflict of interest is declared. We aim to
quantify and determine the effect of author disclosure of conflict of interest on scientific reporting.
Methods: Abstracts from an international spine research meeting (North American Spine Society 2010) were selected that
specifically evaluated a device, biologic, or proprietary procedure. They were then made anonymous to reviewers. An item
of interest was established in each of the abstracts in order to standardize evaluation. Next, three blinded reviewers
independently rated the abstracts as favorable, neutral, or unfavorable with regard to the item of interest. Additionally, the
blinded reviewers attempted to predict whether a related disclosure was made. The meeting disclosure index was used to
tabulate the minimum US dollar value attributable to disclosures.
Results: Of the 344 total abstracts, 76 met inclusion criteria. In 79%, a related conflict of interest was reported. The amount
of the disclosure was incompletely reported in 30% of cases. Where available, it averaged a cumulative minimum of
$219,634 USD per abstract. The results of the abstracts were judged to be favorable, neutral, and unfavorable in 63%, 32%
and 5% of abstracts, respectively. There was no correlation between the presence of a related disclosure and the findings of
the studies (p=0.81), although interpretation of this is limited by a small sample size and an overall apparent bias to report
favorable studies. Additionally, the blinded reviewers were unable to predict whether a related disclosure was made
(p=0.40).
Conclusion: No association existed between the presence of a related disclosure and the results of the studies. While the
actual compliance with reporting a potential conflict of interest is unable to be determined, the value amount related to the
disclosures made was inadequately reported according to meeting guidelines.
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Introduction
Conflict of interest, as it pertains to medicine, occurs when a
physician interest compromises the integrity of the physician-
patient relationship. There is a societal and patient centered
expectation that the treating provider is free from these conflicts
when rendering decisions about medical care. Paradoxically, there
is also the realization that in the current healthcare delivery
system, potential conflicts are unavoidable for the most part.
Indeed, there are many beneficial aspects of commercial alliance,
including research support, clinical product support, and innova-
tion. Therefore, public transparency is expected to exist in order to
improve the impartiality of a de facto impartial arrangement. New
legislation, such as the Physician Payments Sunshine Act, has
recently been enacted to improve transparency of these physician-
industry relationships through mandatory public disclosure. [1]
For the spine surgeon in particular, affiliation with industry
raises concerns for impartiality and conflict of interest. Medical
devices and biologics are rapidly growing staples in the practices of
many spine surgeons and have significant costs at both the
individual and national level. For example, while bone morpho-
genic protein (BMP) is currently only FDA-approved for use in the
lumbar spine, its nationwide usage has increased from 0.69% of
all-level fusions in 2002 to 24.89% of all-level fusions in 2006. [2]
Its usage has been implicated in complications in the anterior
cervical region, while also being associated with greater hospital
charges. [2,3] The rates of spinal fusion overall have also increased
dramatically over recent years and are inherently more costly
procedures than decompression procedures alone. [4–6] The
increased rate of spinal fusion surgery has been linked to an
increased risk of major complications, mortality, and resource use
in older populations. [5] With poor outcome measures and a
paucity of data to suggest improved outcomes associated with the
increased use of these devices/biologics, interest in the potential
for conflicts of interest to contribute to this phenomenon has
grown. [7]
Recognizing this, several parent organizations and governing
bodies have imposed rigorous policies to increase transparency
mandating full disclosure with any research publications, research
projects, meetings, and educational programs. Some of these
policies even require quantitative, categorical identification of
financial relationships. [8] In spite of this requirement, there is
significant variability in the reporting of financial conflicts of
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research, making interpretation difficult. [9]
Beyond patient care and healthcare economics, financial
relationships may influence the outcome of scientific reporting.
Studies have demonstrated that investigators with financials
relationships with the manufacturers of a drug or device are
significantly more likely to report ‘‘positive’’ evaluations of the
intervention as compared to being ‘‘neutral’’ or ‘‘negative’’. [10–
12] Relationships with industry have been associated with
restrictions on publication and data sharing in the scientific
community. [13] Within spine research, in particular, industry
funded studies have been associated with a statistically greater
likelihood of positive results than studies with other funding
sources. [14,15] While these relationships with industry have been
described, along with compliance to reporting the same, no
quantitative analysis has yet been performed. Herein, we analyze
research abstracts from a large, international spine research
meeting known for its rigorous disclosure requirements to identify
the influence of potential conflicts of interest.
Materials and Methods
Each oral presentation abstract from the 2010 North American
Spine Society (North America’s largest multidisciplinary spine
society) annual meeting was reviewed via an online, web-based
archive. An independent individual, blinded to the subsequent
abstract evaluation, selected all abstracts that specifically evaluated
a device, biologic, or proprietary procedure. Identifiable informa-
tion regarding author identity, institution and geographical
location were removed resulting in anonymous abstracts formatted
with title and the body of text. An item of interest was established
in each of the abstracts to standardize evaluation. (For example, if
bone morphogenic protein was identified as an item of interest,
then it would represent the fulcrum point to later assess outcomes).
Next, three blinded reviewers independently rated the abstracts
as favorable, neutral, or unfavorable with regard to the item of
interest. The mode was used to generate a categorical variable.
Additionally, the blinded reviewers attempted to predict whether a
related disclosure was made.
Finally, the 2010 NASS annual meeting disclosure index
(release date May 10, 2010) was used to tabulate the minimum
US dollar value attributable to related royalties, consulting,
speaking & travel arrangements, scientific advisory board work,
and grants or research support, creating a matrix with the abstract
authorship information. [16] Levels of financial association were
previously categorized by the NASS as (A) $100 to 1000, (B) $1001
to 10,000, (C) $10,001 to 25,000, (D) $25,001 to 50,000, (E)
$50,001 to 100,000, (F) $100,001 to 500,000, (G) $500,001 to
1,000,000, (H) $1,000,001 to 2,500,000, and (I) greater than
$2,500,000. Each abstract’s minimum cumulative association was
determined by summating the authors’ individual values based on
the minimum value in the category range. In the absence of exact
dollar amounts, the actual financial association lies somewhere
between the minimum and maximum dollar amounts for each
category. Private investments were noted but not included in the
analysis if they were not obtained as an obvious direct benefit of
the relationship. Non-commercial grants were excluded (e.g.
originating from the National Institutes of Health). Commercial
employee status was identified as an obvious conflict of interest.
Relationships outside of a one-year time period were excluded.
Statistical analysis of the distribution of results was performed with
Prism 5 for Mac (GraphPad Software, Inc). Pearson’s chi-squared
test was utilized to analyze observer determination of favorability
and the occurrence of study disclosure. Fisher’s exact test (two-
sided) was used to analyze observer prediction of the occurrence of
study disclosure and actual occurrence. Fleiss’ kappa was utilized
to assess the degree of inter-observer agreement. Significance was
pre-defined at p,0.05.
Results
There were 344 abstracts in total accepted for presentation. Of
these, 76 met inclusion criteria. In 79% of these abstracts, a related
conflict of interest was reported. The amount of disclosure was
incompletely reported in 30% of cases. The reason for incomplete
disclosure was not reporting the actual dollar amount category of
the disclosure (required by meeting guidelines). Where available, it
averaged a cumulative minimum of $219,634 USD per abstract.
The results of the abstracts were judged by the reviewers to be
favorable, neutral, and unfavorable in 63%, 32% and 5% of
abstracts (mode), respectively. Inter-observer agreement was good
among the three observers (Fleiss’ kappa, 0.411). There was no
correlation between the presence of a conflict of interest and the
findings of the studies (p=0.81). [Figure 1] Additionally, the
blinded reviewers were unable to predict whether a conflict of
interest existed (p=0.40). [Figure 2]
Several notable levels of disclosure were identified: authors were
identified as receiving royalty payments greater than $500,000
(n=5), 1,000,000 (n=2), and 2,500,000 (n=2). One author was
identified as reporting disclosures related to trips or travel of
greater than $500,000.
Discussion
Relationships with device and biologic companies have and will
continue to exist in medicine; the purpose of this study was to
assess the implications of these relationships on the presentation of
scientific research in the spine community. While much has been
written on the potential influence of conflict of interest on medical
and scientific work, our study is the first to use quantitative analysis
to analyze actual dollar amount estimates of related financial
conflicts of interest (self reported). Our analysis failed to find a
correlation between the perceived findings of the abstract and the
presence of a potential conflict of interest. Additionally, because
the choice of words and the tone of the abstract can lead to a
perception of bias, we attempted to increase the reliability of our
findings by asking each independent, blinded reviewer to guess
whether a conflict of interest existed based on the tone of the
abstract. In this study, we report that despite a high percentage of
disclosed conflicts of interest for research studies summating to a
significant amount of money, no apparent influence on reporting
of their outcome was found.
Physicians and scientists are held to the highest ethical standard
of maintaining independence in decision making and data
analysis. Speaking honoraria, consulting contracts, and royalty
payments, must never distort clinical care and research integrity.
Studies have demonstrated that conflict of interest may have
conscious or unconscious effects that lead to the promotion of
devices or off-label use of devices. As a result there is a strong
perception that medical decisions and the completeness and
accuracy of scientific study design and data may be marred by the
accountability to outside commercial interests. Our study supports
the hypothesis that independence in medical decision making may
be preserved despite related conflicts of interest. Critics may argue
that independence is preserved only to a certain monetary level,
yet the available data does not permit an accurate dose-response
relationship analysis.
Several limitations to this study should be noted. Most apparent
is that it is the analysis of a single year and single scientific meeting.
Conflict of Interest in Spine Research
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established. [17] Comparison analysis between multiple meetings
of the same year have identified discrepancies in conflict of interest
reporting, however not all meetings in a given year require
quantification of the disclosure as was necessary for our analysis.
[9]
Another inherent limitation of this study was the fact that only
accepted abstracts were analyzed. It is well known that scientific
studies with positive findings are published more often, and more
quickly, than trials with negative findings, irrespective of their
validity. [18,19] Also known at the ‘‘winner’s curse’’, the current
system of biomedical literature evaluation, publication, and
dissemination distorts the reality of scientific research via a very
strong publication bias in favor of positive results. [20,21] With a
bias towards positive studies, it is difficult to assess the influence of
conflict of interest on study outcome when the majority of studies
presented in an overall small sample size are favorable. Secondary
to this power limitation, a type II error cannot be excluded.
Even if no commercial conflicts of interest are reported, there
may be financial incentives that influence medical practice that are
not currently required to be reported by any scientific organiza-
tion. That is, differential reimbursement patterns exist for surgical
procedures that are difficult to explicitly account for, as universal
fee and charge reporting is not required. Generally, it is well
recognized that spinal fusion procedures reimburse more favorably
than do non-fusion spinal surgery. In the very select Medicare
population studied by Deyo et al., reimbursement for a non-fusion
spinal decompression was estimated at $600–800 USD. [5] For
complex fusions, the reimbursement can be up to 10-fold greater.
[5,22]
Finally, disclosures are not always made, even when significant
conflicts of interest exist. [9,17] There exist no universal database
to allow for centralized reporting and no systems exist to validate
the claims of physicians.
Conclusion
For the 2010 NASS annual meeting abstracts that evaluated a
device, biologic, or proprietary procedure, no association existed
between the presence of a conflict of interest and the results of the
studies. While the actual compliance with reporting a conflict of
interest is undetermined, the value amount related to the
disclosures made was inadequately reported.
Figure 1. Observer interpretation of study favorability. Three independent and blinded researchers assessed the favorability of the results of
an abstract with respect to a designated item of interest. There was no association with these ratings and whether a related conflict of interest was
present (p=0.81).
doi:10.1371/journal.pone.0044327.g001
Figure 2. Observer prediction of disclosure declaration. Three independent and blinded researchers were unable to predict whether a related
conflict of interest was present for each abstract (p=0.40).
doi:10.1371/journal.pone.0044327.g002
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